Osteo-Pharma BV is a biotechnology and pharmaceutical company that focuses on developing innovative medication and medical devices for orthopedic and dental applications, specifically for the local treatment of bone fractures and defects. Founded in 2014, Osteo-Pharma's technology platform revolves around the sustained delivery of low molecular weight compounds that not only enhance bone formation but also inhibit bone resorption.
The company's proprietary technology involves encapsulating pharmaceuticals in a biodegradable carrier, enabling the sustained release of these pharmaceuticals over a 6-8 week period. This approach has shown promising results in enhancing bone growth and inhibiting bone resorption, ultimately leading to improved bone healing. Osteo-Pharma's technology is currently under development to address bone fractures, bone defects, and osteoarthritis treatment.
Moreover, Osteo-Pharma is also working on a novel coating for dental and orthopedic implants, aiming to enhance osseo-integration and prevent implant loosening. The company's innovative approach and focus on addressing critical unmet needs in the orthopedic and dental fields position it as a key player in the biotechnology and pharmaceutical industries.
There is no investment information
No recent news or press coverage available for Osteo-Pharma BV.
We care about your data, and we'd love to use cookies make your experience better.
